Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients

Joost F. Swart,Sytze de Roock,Rutger A. J. Nievelstein,Ineke Slaper-Cortenbach,Jaap J. Boelens,Nico Wulffraat

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients

2019

Joost F. Swart
Sytze de Roock
Rutger A. J. Nievelstein
Ineke Slaper-Cortenbach
Jaap J. Boelens
Nico Wulffraat

Objectives To compare the total number of adverse events (AEs) before and after mesenchymal stromal cell (MSC) infusion in refractory JIA and to evaluate its effectiveness.

Keywords:

Bone marrow
Refractory
Physical therapy
Diabetes mellitus
Mesenchymal stem cell
Arthritis
Pathology
Medicine
Juvenile
Methotrexate
Tocilizumab
Discontinuation
Internal medicine
Rheumatology
Gastroenterology
Infusion Procedure
Adverse effect
Macrophage activation syndrome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations